

**Title:**

**Does pre-operative urodynamics lead to better outcomes in management of urinary incontinence in women? A linked systematic review and meta-analysis**

**Authors:**

**Dr Kar Yee Lor MBChB<sup>1</sup> and Maria Soupashi, BSc (Honours)<sup>1</sup>**

**Prof Mohamed Abdel-Fattah, FRCOG, M.D.<sup>2</sup>**

**Dr Alyaa Mostafa ♠, MB B Ch, MD, DipMED, FHEA<sup>3</sup>**

<sup>1</sup>Medical Student - University of Aberdeen, Aberdeen, UK

<sup>2</sup>Clinical Chair in Gynaecology / Consultant Gynaecologist & Sub-specialist Urogynaecologist - University of Aberdeen, Aberdeen, UK

<sup>3</sup>Clinical lecturer - University of Aberdeen, Aberdeen, UK

**♠ Corresponding Author: Dr Alyaa Mostafa**

Clinical Lecturer

School of Medicine, Medical Sciences and Nutrition, University of Aberdeen

Address: Second Floor, Aberdeen Maternity Hospital, Foresterhill, Aberdeen, AB25 2ZD, UK

Tel: 01224 438422

E-mail: [a.mostafa@abdn.ac.uk](mailto:a.mostafa@abdn.ac.uk)

**Conflict of interests:**

M.A.F is the chief investigator and A.M. is a co-investigator on the ongoing National Institute for Health Research (NIHR)-funded FUTURE Study evaluating the clinical and cost effectiveness of urodynamics in women with refractory overactive bladder symptoms (<https://w3.abdn.ac.uk/hsru/FUTURE/Public/Public/index>). They are also part of the team applying for further relevant NIHR funding. Professor Abdel-Fattah and Dr. Mostafa have no potential conflicts of interest for this study. For the full declaration by Professor Abdel-Fattah please see this weblink <https://www.abdn.ac.uk/iahs/research/obsgynae/profiles/m.abdelfattah>. K.Y.L and M.S. report no conflict of interest.

**Source of funding:**

K.Y.L received an Innes Will Endowed Scholarship through the University of Aberdeen Development Trust for medical research. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript for publication.

1 **Does pre-operative urodynamics lead to better outcomes in management of urinary**  
2 **incontinence in women? A linked systematic review and meta-analysis**  
3

4  
5 Lor KY, Soupashi M, Abdel-Fattah M, Mostafa A  
6

7  
8  
9 **ABSTRACT**  
10

11  
12 The use of preoperative urodynamics as a standard investigation for urinary incontinence  
13 (UI) has long been a subject of debate, with a lack of robust evidence to demonstrate  
14 improved patients' outcomes. We aim to compare the clinical and cost effectiveness of  
15 urodynamics versus office clinical evaluation only, prior to the treatment of UI. We  
16 conducted three linked systematic reviews and meta-analyses of randomised controlled trials  
17 (RCTs) comparing urodynamics assessment versus clinical evaluation only in women prior to  
18 1) non-surgical treatment of UI, 2a) surgical treatment of stress urinary incontinence (SUI)  
19 and 2b) invasive treatment for overactive bladder (OAB). Women with severe pelvic organ  
20 prolapse, previous continence surgery and neuropathic bladder were excluded. Primary  
21 outcomes were patient-reported and objective success post-treatment. Secondary outcomes  
22 were adverse events, quality of life, sexual function and health economic measures. We  
23 searched MEDLINE, Embase and Cochrane Central Register of Controlled Trials databases  
24 for each category, which was last updated on January 2019. Study selection, risk of bias  
25 assessment and data extraction were performed independently by two reviewers. The random  
26 effects model was used to assess risk ratio and mean difference with 95% confidence interval.  
27 Statistical heterogeneity was assessed by  $I^2$  statistics and the quality of evidence by the  
28 Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)  
29 approach.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Four RCTs compared urodynamics versus clinical evaluation only prior to non-surgical  
2 management of UI. Treatment consisted of pelvic floor muscle training, with or without  
3 pharmacological therapy. Meta-analysis of 150 women showed no evidence of significant  
4 difference in the patient-reported and objective success rates between groups (P=0.520, RR:  
5 0.91, 95% CI 0.69-1.21,  $I^2 = 0\%$  and P=0.470, RR:0.87, 95% CI 0.59-1.28,  $I^2 = n/a$ ,  
6 respectively). Seven RCTs were identified for surgical management of SUI. The majority of  
7 women underwent mid-urethral tape procedures (retropubic or transobturator approach).  
8 Meta-analysis of 1,149 women showed no evidence of significant difference in patient-  
9 reported (P=0.850, RR:1.01, 95% CI 0.88-1.16,  $I^2 = 53\%$ ) and objective success between  
10 groups (P=0.630, RR:1.02, 95% CI 0.95-1.08,  $I^2 = 28\%$ ). There was no significant difference  
11 in incidence of voiding dysfunction, *de novo* urgency, and urinary tract infection between  
12 groups. No RCTs were identified for invasive management of OAB.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 In conclusion, limited evidence shows that routine urodynamics prior to non-surgical  
31 management of UI or surgical management of SUI is not associated with improved treatment  
32 outcomes, when compared to clinical evaluation only. Well-designed clinical trials are  
33 needed to evaluate the clinical and cost-effectiveness of routine urodynamics prior to surgical  
34 management of SUI and OAB.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 **Key words:**

47 Urodynamics; clinical evaluation; stress urinary incontinence; overactive bladder; surgical  
48 outcome  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1. Introduction

1  
2  
3 Urinary incontinence (UI) is a common problem affecting women of all ages, and can have a  
4 profound impact on their physical and psychosocial wellbeing as well as their quality of life  
5  
6 (QoL) [1,2].  
7  
8  
9

10  
11  
12 A longitudinal study [3] of 2025 women aged  $\geq 65$  years reported the baseline prevalence of  
13 urgency urinary incontinence (UUI) and stress urinary incontinence (SUI) to be 36.3% and  
14  
15 40.3% respectively. Data from the European Prospective Investigation into Cancer and  
16  
17 Nutrition (EPIC) study estimated that 1.3 billion females  $\geq 20$  years worldwide suffer from  
18  
19 lower urinary tract symptoms (LUTS), with a projected increase to 1.6 billion in 2018 [4].  
20  
21  
22  
23  
24  
25  
26  
27

28 The current standard for clinical assessment of women with UI includes detailed history to  
29  
30 determine the type of UI; risk factors and possible associating symptoms such as voiding  
31  
32 difficulties, recurrent urinary tract infection (UTI), prolapse, sexual or bowel symptoms. The  
33  
34 assessment also includes examination (for pelvic masses or pelvic organ prolapse (POP)), the  
35  
36 use of specific tools such as bladder diaries, validated symptom severity questionnaires as  
37  
38 well as non-invasive tests such as stress test and bladder scan to assess post-voiding residual  
39  
40 volume (PVR).  
41  
42  
43  
44  
45  
46

47 The bladder has traditionally been labelled as an “unreliable witness” [5], hence the vast  
48  
49 majority of clinicians recommend further investigation of UI with urodynamics to confirm  
50  
51 the diagnosis and establish any concomitant pathology prior to any invasive treatment.  
52  
53

54 Urodynamics aims to evaluate the neuromuscular function of the bladder and urethra as well  
55  
56 as demonstrate an underlying abnormality of storage or voiding. Urodynamics includes non-  
57  
58 invasive tests such as uroflowmetry, and invasive tests such as multichannel filling  
59  
60  
61  
62  
63  
64  
65

1 cystometry with or without Valsalva leak-point pressures (VLPP), urethral pressure studies  
2 and pressure flow studies (PFS) [6]. Results from urodynamics assessments are also used to  
3  
4 counsel women regarding their suitability for surgery and their expected outcomes and/or  
5  
6 adverse events.  
7  
8  
9

10  
11 For patients, urodynamics can be perceived to be invasive, uncomfortable, associated with an  
12  
13 element of emotional distress and carries the risk of developing UTI (3–5%) [4,7-9].  
14  
15

16  
17 However, most women find urodynamics to be acceptable provided it will improve their  
18  
19 outcomes post-treatment [9-12].  
20  
21  
22

23  
24 A large survey of urologists and urogynecologists in the United Kingdom (UK) showed that  
25  
26 90% would routinely perform urodynamics prior to surgery in women with SUI or stress-  
27  
28 predominant mixed urinary incontinence (MUI) [13]. A systematic review and meta-analysis  
29  
30 in 2014 suggested that routinely performing urodynamics had no impact on patient-reported  
31  
32 outcomes for those undergoing surgical treatment for “pure SUI” symptoms compared to  
33  
34 standard clinical assessment [14]. The study included three randomised controlled trials  
35  
36 (RCTs) with a small number of women (n=775). A Cochrane review also reached similar  
37  
38 results [15], with authors reporting a small number of included studies and an increased risk  
39  
40 of bias.  
41  
42  
43  
44  
45  
46  
47

48 We performed a linked systematic review and meta-analyses to provide the most up-to-date  
49  
50 evidence on clinical and cost-effectiveness of routine invasive urodynamics investigation  
51  
52 compared to clinical evaluation only, prior to non-surgical treatments of UI and surgical  
53  
54 treatments for women with SUI and overactive bladder (OAB).  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2. Methods

Three linked systematic reviews and meta-analyses of RCTs were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement guidance [16]. The eligibility criteria for included studies were all RCTs comparing the use of urodynamics investigation as part of assessment versus clinical evaluation only in three categories of women with UI prior to 1) non-surgical treatment of UI, 2a) surgical treatment of SUI and 2b) invasive treatment for OAB. The inclusion criteria for the non-surgical treatment of UI review included all women with UI symptoms including SUI, OAB or MUI. For the surgical treatment of SUI review, the inclusion criteria were women with SUI or MUI with predominant SUI symptoms, while for the invasive treatment for OAB review, women were included if they had OAB or urgency predominant MUI symptoms. Exclusion criteria for all groups were: neuropathic bladder, concomitant severe POP and previous continence surgery.

Primary outcomes were: i) patient-reported success (cure or improvement) of UI and ii) objective success (cure or improvement). Secondary outcomes were i) adverse events (i.e. voiding dysfunction, *de novo* urgency, UTI), ii) impact on QoL, iii) sexual function and iv) health economic measures such as cost-effectiveness of the interventions and cost/resource implications to health services.

The literature searches were last updated on January 2019 using MEDLINE, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) databases. A manual search of

1 relevant conferences and bibliographies of relevant reviews was carried out. Search criteria  
2 were limited to human and females, while no language restrictions were applied.  
3  
4

5  
6  
7 The search was performed independently by two authors (KYL and MS) and included  
8  
9 Medical Subject Heading subheadings, word variations, and free text such as urodynamics,  
10  
11 clinical evaluation, urinary incontinence, stress urinary incontinence, urgency incontinence,  
12  
13 overactive bladder, conservative management, pharmacological management, and surgical  
14  
15 outcome.  
16  
17

18  
19  
20  
21 Full-text articles were independently screened and assessed for eligibility by two authors  
22  
23 (KYL and MS). A third author (AM) resolved any discrepancies. Two authors (KYL and  
24  
25 MS) independently performed data extraction and assessed risk of bias of included RCTs in  
26  
27 accordance with the Cochrane Handbook for Systematic Reviews of Intervention [17].  
28  
29

30  
31 Primary authors for all selected RCTs were contacted to request for supplementary data.  
32

33  
34 Table 1 shows a list of the included RCTs for each review. The Grading of  
35  
36 Recommendations, Assessment, Development and Evaluation (GRADE) methodology was  
37  
38 used to assess the quality of evidence and interpret findings for primary outcomes and any  
39  
40 secondary outcomes able to be pooled into a meta-analysis [18].  
41  
42  
43

44  
45  
46 Data were analysed using RevMan v.5.2.20 (Cochrane Collaboration, Oxford, UK) [19].  
47

48  
49 Meta-analysis results were expressed as risk ratios (RR) with 95% confidence intervals (CI)  
50  
51 for dichotomous variables using the Mantel-Haenszel method [20]. Statistical heterogeneity  
52  
53 was measured using the chi-square test and  $I^2$  scores, and methodological heterogeneity was  
54  
55 assessed during selection. To control for the effect of unobserved heterogeneity, the random  
56  
57 effects model was used throughout [21]. Sensitivity analysis was performed for primary  
58  
59  
60  
61  
62  
63  
64  
65

1 outcomes by excluding conference abstracts for which results were not published in full-text  
2 publications.  
3  
4  
5  
6  
7  
8

### 9 **3. Results**

#### 10 *3.1 Non-surgical management of UI review:*

11  
12 The literature search (Fig.1) generated 1647 studies with an additional six studies identified  
13 manually. Full-text articles were reviewed for nine studies and four RCTs were selected to be  
14 included in this review.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 Three RCTs [22-24] were conducted in the UK and one [25] in Norway. One study was a  
26 conference abstract [23]. The mean follow-up was 14.3 months (SD:14.97 months; range:3-  
27 36 months). Three RCTs [23-25] reported pharmacological therapy in addition to pelvic floor  
28 exercises within their non-surgical management plan.  
29  
30  
31  
32  
33  
34  
35  
36

37 Two RCTs [22,25] (n= 150 women) included suitable data available to be pooled and  
38 included in the meta-analysis (n=73 women in urodynamics group, n=77 women in clinical  
39 evaluation group). There was no statistically significant difference in patient-reported success  
40 rates after non-surgical treatment for UI between the urodynamics group and the clinical  
41 evaluation only group (P=0.520, RR:0.91, 95% CI, 0.69-1.2, GRADE quality of evidence:  
42 low) (Fig.2a). Only one RCT [22] provided outcomes on objective success, defined as being  
43 dry on pad testing. This RCT showed no evidence of significant difference between both  
44 groups (P=0.470, RR:0.87, 95% CI, 0.59-1.28, GRADE quality of evidence: very low)  
45 (Fig.2b). None of the RCTs reported any adverse events post-treatment.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 Similarly, there were no statistically significant differences between groups in QoL  
2 improvement assessed by the King's Health Questionnaire (KHQ) ( $P>0.05$ ), reported in only  
3 one RCT [24]. No RCTs reported data regarding the impact on sexual function or health  
4 economic measures.  
5  
6  
7  
8  
9

10  
11 For patient-reported cure/improvement, the statistical heterogeneity was estimated to be low  
12 ( $I^2 < 25\%$ ). Risk of bias was assessed using the Cochrane Collaboration Risk of Bias  
13 Assessment graph (Fig.3a,b). Most RCTs demonstrated good random sequence generation,  
14 with 50% demonstrating adequate allocation concealment, blinding of outcome assessor and  
15 rates of incomplete outcome data.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 *3.2 Surgical management of SUI review*

27  
28  
29  
30

31 The literature search (Fig.4) generated 331 studies, with 12 additional studies identified  
32 manually. Full articles were reviewed for 26 studies. Seven RCTs were included [23,26-31],  
33 with six having suitable data to be included in the meta-analysis [26-31]. One of the studies  
34 [27] was a feasibility study, which included a multi-centre randomised pilot trial with  
35 relevant outcomes being reported. Another study, Agarwal et al, [31] made a post-  
36 randomisation exclusion of 12 women (28.6%) in the urodynamics arm in accordance with  
37 their pre-specified RCT protocol for women with unfavourable urodynamics parameters.  
38  
39 Four RCTs [23,27,29,30] were conducted in European countries, two in the United States of  
40 America [26,28] and one in India [31]. Three of the RCTs were abstracts [23,26,29].  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 The mean follow-up was 23.1 months (SD: 15.1 months; range: 6 – 47.5 months). There was  
57 variation in urodynamics parameters studied in each RCT, with VLPP and PFS being the  
58  
59  
60  
61  
62  
63  
64  
65

1 most commonly assessed. Mid-urethral tapes (retropubic or transobturator approach) were the  
2 predominant surgical interventions used in all RCTs, while a very small number underwent  
3 colposuspension, urethropexy or urethral bulking.  
4  
5  
6  
7  
8

9 Patient-reported success was evaluated using standardised questionnaires such as Urogenital  
10 Distress Inventory Scale and Patient Global Impression of Improvement (PGI-I) scale  
11 [28,30]. Five RCTs (n =1069; women n=542 in the urodynamics group, n =527 in the clinical  
12 assessment only group) included relevant patient-reported outcomes with 234 women,  
13 (21.9%) lost to follow-up. Meta-analysis showed no evidence of significant difference in  
14 patient-reported success rates between the urodynamics and clinical evaluation only groups  
15 (P=0.850, RR:1.01, 95% CI 0.88-1.16, GRADE quality of evidence: low) (Fig.5a). The  
16 results were consistent after conducting a sensitivity analysis [31] excluding abstracts and  
17 Agarwal et al. (P=0.340, RR:0.90, 95% CI, 0.74-1.11). Objective success was defined as a  
18 negative stress test in five RCTs (n=927 women; n= 470 in the urodynamics group, n=457 in  
19 the clinical evaluation only group) with 104 women (11.2%) lost to follow-up. Meta-analysis  
20 showed no evidence of a significant difference (P=0.630, RR:1.02, 95% CI 0.95-1.08,  
21 GRADE quality of evidence: moderate) between the two groups (Fig.5b). The results  
22 pertained on sensitivity analysis (P=0.190, RR:0.95, 95% CI, 0.89-1.02). Meta-analysis for  
23 adverse events showed no evidence of significant differences between both groups for *de*  
24 *novo* urgency/ urgency incontinence (P=0.640, RR:1.16, 95% CI, 0.62-2.17) and UTI  
25 (P=0.970, RR:0.99, 95% CI, 0.51-1.90). Data from two RCTs showed a non-significant trend  
26 favouring urodynamics for voiding dysfunction (P=0.360, RR:0.65, 95% CI, 0.26-1.64)  
27 (Fig.6).  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 QoL was assessed using the incontinence quality of life (I-QoL) questionnaire [29],  
2 International Consultation on Incontinence Modular Questionnaire Lower Urinary Tract  
3 Symptoms Quality of Life (ICIQ-LUTSqol) [27] and Incontinence Impact Questionnaire  
4 (IIQ) [28]. Data from these RCTs individually showed no significant differences between  
5 groups with regards to the impact on QoL, but due to the different tools used, it was not  
6 possible to conduct a meta-analysis.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 Impact on sexual function was not reported in any of the studies. Health economic evaluation  
18 was reported in one study [27], which demonstrated a mean difference in total average cost of  
19 £138 (p=0.071) per woman favouring urodynamics.  
20  
21  
22  
23  
24  
25

26 In this review, no studies were excluded due to methodological heterogeneity. For patient-  
27 reported and objective cure/improvement, the statistical heterogeneity was estimated to be  
28 moderate ( $I^2$ :25%-75%). Voiding dysfunction, *de novo* urgency as well as UTI incidence  
29 rates demonstrated low heterogeneity ( $I^2$ <25%). Risk of bias was assessed using a Cochrane  
30 Collaboration Risk of Bias Assessment graph (Fig.7a,b). Random sequence generation was  
31 appropriately described in three studies, while only a few described adequate methods of  
32 allocation concealment and blinding of outcomes assessor.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 *3.3 Invasive management of UUI/OAB review*

47  
48  
49  
50

51 The literature search generated n=211 studies with an additional study identified manually.  
52 Full-text articles were reviewed for four studies. No RCTs were available to assess the  
53 clinical and cost effectiveness of urodynamics versus clinical evaluation only, in women with  
54 OAB prior to invasive or surgical treatment (Fig.8).  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

#### 4. Discussion

The paucity of robust evidence on the clinical and cost-effectiveness of routine urodynamics assessment, especially prior to surgical or invasive management of female UI (both SUI and OAB), represents a dilemma to patients and clinicians as well as policymakers.

This review found no evidence of significant differences in patient-reported and objective success (cure/improvement) rates between women assessed by urodynamics versus clinical evaluation only prior to non-surgical management of UI (SUI and OAB). The fact that urodynamics assessment is not required prior to commencing non-surgical treatment of any type of UI is now considered standard clinical practice and is in agreement with the NICE (UK) and European Association of Urology guidelines [32]. Similarly, no statistically significant differences in treatment outcomes were observed between women assessed by urodynamics versus clinical evaluation only prior to surgical management for SUI. However, the GRADE quality of evidence for these outcomes were moderate and low respectively. No RCTs were available to assess the role of urodynamics prior to the invasive management of OAB.

Urodynamics has been traditionally used to help clinicians establish the correct diagnosis for the type of UI and also to plan the appropriate surgical treatment for individual patients. A systematic review [33] in 2011 which included 23 studies involving 6,282 women, showed that a “clinical diagnosis” of SUI was re-diagnosed into MUI and detrusor overactivity (DO) in only 9% and 7% of cases respectively following urodynamics. Findings differed for clinical diagnosis of MUI, which was re-classified to pure SUI in 46% of women and to DO in 21%. The authors concluded that the importance of urodynamics for diagnosing different

1 types of UI was unclear and recommended the need for further research to evaluate their  
2 effect on treatment outcomes.  
3

4  
5  
6  
7 Two retrospective studies assessing outcomes of tension-free vaginal tape (TVT) in 264  
8 women, showed an association between pre-operative VLPP <60 cm H<sub>2</sub>O and a lower  
9 success rate [34-35]. Houwert et al. collected data from 387 patients who underwent mid-  
10 urethral tape procedures and showed that specific parameters could also lead to a more  
11 individualised selection for the type of mid-urethral tape to be used: DO was associated with  
12 a higher failure rate following retropubic TVT while low maximum urethral closure pressure  
13 (MUCP) was associated with lower success rates for transobturator tape (TOT) [36].  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Interestingly, a Dutch survey in 2011 completed by gynaecologists (n=103) and urologists  
27 (n=60) representing 80 hospitals, has shown that only 37% performed urodynamics as part of  
28 routine investigation prior to SUI surgery, while 88% stated that a positive stress test during  
29 clinical examination would be sufficient for them to proceed with surgery. In this review, the  
30 commonest indications for urodynamics prior to surgery were symptoms indicating possible  
31 DO such as urgency [37]. Another survey in 2012 of gynaecologists (n=400) and  
32 urogynaecologists (n=200) conducted in the UK showed that the majority of surgeons agreed  
33 that urinary diary (95.8%), free uroflowmetry (94.2%), multichannel subtraction filling  
34 cystometry (99.5%), and voiding cystometry (98%) should be amongst the tools for UI  
35 assessment when contemplating secondary surgery [38].  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 A secondary analysis of the VALUE trial reported that clinicians are reluctant to omit  
53 urodynamics prior to UI management especially pre-operatively as the diagnosis could be  
54 revised following findings, possibly modifying the treatment plan. However, despite  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 urodynamics' propensity to significantly change the clinical diagnosis, the clinician/surgeon  
2 rarely made cancellations or modifications to the surgery or revised any conservative  
3 treatment plan [39].  
4  
5  
6  
7  
8

9 Urodynamics can be seen as a useful tool for clinicians to predict the likelihood of  
10 postoperative adverse events [33], however, the current evidence to support this hypothesis is  
11 scarce. A retrospective study investigating postoperative voiding dysfunction in women  
12 (n=159) who underwent TOT surgery for SUI reported that maximum flow rate (Q-Max)  
13 <15ml/s was associated with the likelihood of developing postoperative voiding dysfunction  
14 [40]. However, a secondary analysis of an RCT (n=341) of two different types of TOT has  
15 shown that none of the pre-operative urodynamics parameters have affected the likelihood of  
16 postoperative voiding dysfunction [41]. Similarly, the secondary analysis of the VALUE trial  
17 reported that women who had their treatment plan changed based on voiding phase  
18 measurements did not have decreased odds of voiding dysfunction [39]. Our meta-analysis  
19 demonstrates that urodynamics prior to surgery of SUI did not improve the incidence of  
20 postoperative *de novo* urgency and UTI, however, a non-significant trend was observed  
21 favouring urodynamics for voiding dysfunction.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 A secondary analysis of the INVESTIGATE-I trial assessed the cost-effectiveness of  
45 urodynamics and demonstrated a mean difference in total average cost of £138 (p=0.071) per  
46 woman favouring routine urodynamics prior to surgery for SUI. This difference is partly due  
47 to fewer women undergoing surgical management in the urodynamics group, and the fact that  
48 costs of non-invasive investigations were excluded in the cost-utility analysis. The study was  
49 not powered to provide statistically significant results as it was a mixed-methods study to  
50 assess the feasibility of a future definitive RCT [42]. Conversely, the secondary analysis of  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 the VALUE trial estimated that omitting urodynamics from the pre-operative clinical  
2 assessment in women with uncomplicated SUI could potentially save 13 to 33 million US  
3 dollars every year [43].  
4  
5  
6  
7  
8

9 The paucity of evidence is even more pronounced for the clinical and cost-effectiveness of  
10 routine urodynamics prior to invasive treatments for OAB. A large retrospective study  
11 (n=4500) showed that only 54.2% of women with OAB symptoms had proven DO diagnosed  
12 upon urodynamics. Interestingly, 72.4% of women with DO demonstrated on urodynamics  
13 had no prior OAB symptoms [44]. Despite the above, the results from a recent observational  
14 study (n=666) embedded within the Bladder Ultrasound Study (BUS) RCT, suggested that  
15 clinicians and patients were partly guided by the urodynamics diagnosis while selecting  
16 treatment options [9].  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 An RCT by Rovner et al. of onabotulinumtoxin-A (BoNT-A) versus placebo suggested that  
32 successful treatment outcomes of patients with OAB did not appear to be related to the  
33 preoperative urodynamics diagnosis of DO [45]. Similarly, a placebo-controlled RCT showed  
34 that approximately 60% of the women who received BoNT-A had a positive clinical response  
35 based on the PGI-I [46]. Urodynamics is also considered a standard practice prior to Sacral  
36 Neuromodulation (SNM) treatment of OAB. A recent observational study concluded that  
37 preoperative diagnosis of DO should not be a prerequisite for SNM, given that clinical  
38 improvement for those with confirmed DO have comparable clinical improvement to those  
39 without [47]. However, there is not much evidence on whether the best indicator for a  
40 successful SNM is the presence of DO on urodynamics compared to a positive SNM lead  
41 test.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Our review showed that there are currently no RCT data to assess the role of urodynamics  
2 prior to invasive management of OAB. Results are awaited from a large multi-centre RCT  
3 (FUTURE Study) currently underway in the UK, assessing the clinical and cost-effectiveness  
4 of routine urodynamics in women with refractory OAB [48].  
5  
6  
7  
8  
9

10  
11 This comprehensive linked systematic review presents the most up-to-date evidence from  
12 RCTs comparing the impact of routine urodynamics assessment versus clinical evaluation  
13 only, on the most relevant outcomes for women after non-surgical and surgical management  
14 of UI. Such evidence is required in order to support patients', clinicians' as well as  
15 policymakers' decisions regarding the use of urodynamics. The quality of any systematic  
16 review depends on the quality of the RCTs and the completeness of the datasets. The overall  
17 quality of evidence of the included RCTs was assessed using the GRADE methodology, and  
18 sensitivity analyses were performed for a more robust interpretation of our findings. All  
19 authors have been contacted for missing data. This systematic review and meta-analyses  
20 would be of interest to countries or healthcare systems with limited resources so that better-  
21 informed decisions can be made regarding funding allocation without compromising patient  
22 safety.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 We acknowledge a number of limitations such as the small number of included studies;  
45 however, this is a reflection of the surprisingly limited number of RCTs in this field despite  
46 the widespread use of urodynamics in clinical practice and the high prevalence of UI. There  
47 is a high level of heterogeneity between the RCTs included, especially with regards to patient  
48 population and outcome assessment methods (Table 1), and hence the random effect model  
49 was used. The wide range of patients' presenting symptoms and baseline characteristics as  
50 well as the intra and inter-study variation of urodynamics measurements performed may have  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 had an effect on the results. As studies in this review did not provide separate outcomes for  
2 different subtypes of presenting symptoms (i.e. pure SUI and stress-predominant MUI  
3 separately), subgroup analyses were not possible.  
4  
5  
6  
7  
8  
9

10 This systematic review does not address the value of urodynamics for women with previous  
11 continence surgery, UI resulting from neurological disease and/or significant associated POP.  
12  
13  
14  
15  
16

17 The RCTs included were all evaluating the effectiveness of urodynamics as a diagnostic test,  
18 for which blinding of both patients and assessors was not possible. Hence, study types such  
19 as prospective and retrospective analyses of large databases might provide additional  
20 valuable information for evaluating the role of urodynamics in the treatment of incontinence.  
21  
22  
23  
24  
25  
26  
27  
28

## 29 **5. Conclusions**

30  
31  
32  
33

34 There is no robust evidence to show significantly better outcomes in patient-reported and  
35 objective success with the routine use of urodynamics versus clinical evaluation only, prior to  
36 non-surgical treatments of UI and surgical treatments of SUI in women. No evidence was  
37 found on the role of urodynamics prior to the invasive management of OAB. The results need  
38 to be interpreted with caution due to the small sample size, the quality of RCTs as well as the  
39 vast heterogeneity between studies. This review highlights the need for well-designed RCTs  
40 to address the clinical and cost-effectiveness of routine urodynamics prior to surgical  
41 managements of SUI and OAB.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## 56 **Acknowledgments**

57  
58  
59  
60  
61  
62  
63  
64  
65

We would like to thank the University of Aberdeen statisticians for their support throughout and all RCT authors who have addressed our enquiries.

### Source of funding

K.Y.L received an Innes Will Endowed Scholarship through the University of Aberdeen Development Trust for medical research. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript for publication.

### References

- [1] Farage M, Miller K, Berardesca E, Maibach H. Psychosocial and societal burden of incontinence in the aged population: a review. *Arch of Gynecol Obstet* 2007;277(4):285-290.
- [2] Kwon B, Kim G, Son Y, Roh Y, You M. Quality of Life of Women with Urinary Incontinence: A Systematic Literature Review. *Int Neurourol J.* 2010;14(3):133.
- [3] Nygaard IE, Lemke JH. Urinary incontinence in rural older women: prevalence, incidence and remission. *J Am Geriatr Soc* 1996 Sep;44(9):1049-1054.
- [4] Irwin D, Kopp Z, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. *BJU International* 2011;108(7):1132-1138.
- [5] Bates CP, Whiteside CG, Turner-Warwick R (1970) Synchronous cine-pressure-flow-cysto-urethrography with special reference to stress and urge incontinence. *Br J Urol* 42(6):714-723
- [6] Martin J, Williams K, Abrams K, Turner D, Sutton A, Chapple C et al. Systematic review and evaluation of methods of assessing urinary incontinence. *Health Technol Assess.* 2006;10(6).
- [7] Ku J, Kim S, Kim H, Paick J, Son H, Oh S. Patient experience with a urodynamic study: a prospective study in 208 patients. *J Urol* 2004;171(6 Part 1):2307-2310.

- 1 [8] Foon R, Tooze-Hobson P, Latthe P. Prophylactic antibiotics to reduce the risk of urinary  
2 tract infections after urodynamic studies. *Cochrane Database of Systematic Reviews*.  
3 2012;(10):CD008224.
- 4 [9] Rachaneni S, McCooty S, Middleton L, Parker V, Daniels J, Coomarasamy A et al.  
5 Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and  
6 economic evaluation. *Health Technol Assess* 2016;20(7):1-150.
- 7 [10] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence,  
8 overactive bladder, and other lower urinary tract symptoms in five countries: results of  
9 the EPIC study. *Eur Urol* 2006;50:1306,14; discussion 1314-5.
- 10 [11] Digesu GA, Salvatore S, Fernando R, Khullar V. Mixed urinary symptoms: what are the  
11 urodynamic findings? *Neurourol Urodyn* 2008;27:372-5.
- 12 [12] Mobley DF, Baum N. Etiology, evaluation, and management of nocturia in elderly men  
13 and women. *Postgrad Med* 2014;126:147-53.
- 14 [13] Hilton P, Bryant A, Howel D, McColl E, Buckley B, Lucas M et al. Assessing  
15 professional equipoise and views about a future clinical trial of invasive urodynamics  
16 prior to surgery for stress urinary incontinence in women: A survey within a mixed  
17 methods feasibility study. *Neurourol Urodyn* 2012;31(8):1223-1230.
- 18 [14] Rachaneni S, Latthe P. Does preoperative urodynamics improve outcomes for women  
19 undergoing surgery for stress urinary incontinence? A systematic review and meta-  
20 analysis. *BJOG* 2014;122(1):8-16.
- 21 [15] Clement K, Lapitan M, Omar M, Glazener C. Urodynamic studies for management of  
22 urinary incontinence in children and adults. *Cochrane Database of Systematic Reviews*.  
23 2013.
- 24 [16] Moher D, Liberati A, Tetzlaff J, Altman D. Preferred Reporting Items for Systematic  
25 Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Medicine*.  
26 2009;6(7):e1000097.
- 27 [17] Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of*  
28 *Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.*  
29 Available from <http://handbook.cochrane.org>.
- 30 [18] Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter  
31 12: Interpreting results and drawing conclusions. In Higgins JP, Green S, editor(s).  
32 *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated*  
33 *March 2011]. The Cochrane Collaboration, 2011. Available from*  
34 *handbook.cochrane.org*.
- 35 [19] Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic  
36 Cochrane Centre, The Cochrane Collaboration, 2014.
- 37 [20] Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-  
38 Haenszel Procedure. *J Am Stat Assoc* 1963;58(303):690
- 39 [21] Galecki A, Burzykowski T. *Linear mixed-effects models using R*. New York: Springer;  
40 2013.
- 41 [22] Ramsay I, Ali H, Hunter M, Stark D, Donaldson K. A randomised controlled trial of  
42 urodynamic investigations prior to conservative treatment of urinary incontinence in the  
43 female. *Int Urogynecol J Pelvic Floor Dysfunct* 1995;6(5):277-281.
- 44 [23] Khullar V, Salvatore S, Cardozo L, Howland E, Digesu A, Kelleher C, et al.  
45 Randomised study of ambulatory urodynamics versus symptomatic treatment of  
46 symptomatic women without a urodynamic diagnosis. *Proceedings of the International*  
47 *Continence Society (ICS), 30th Annual Meeting; 2000 Aug 28-31; Tampere, Finland.*  
48 2000.
- 49 [24] Majumdar A, Latthe P, Tooze-Hobson P. Urodynamics prior to treatment as an  
50 intervention: a pilot study. *Neurourol Urodyn*. 2010;29:522-6.
- 51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [25] Høltedahl K, Verelst M, Schiefloe A. A population based, randomised, controlled trial of  
2 conservative treatment for urinary incontinence in women. *Acta Obstet Gynecol Scand*  
3 1998;77(6):671-677.
- 4 [26] Choe JM. Sling surgery performed with and without preoperative urodynamics: a  
5 comparative outcomes analysis (Abstract). Proceedings of the International Continence  
6 Society (ICS), 31st Annual Meeting; 2001 Sept 18-21;Seoul, Korea. 2001:Abstract 175.
- 7 [27] Hilton P, Armstrong N, Brennan C, Howel D, Shen J, Bryant A et al. INVESTIGATE-I  
8 (INVasive Evaluation before Surgical Treatment of Incontinence Gives Added  
9 Therapeutic Effect?): a mixed-methods study to assess the feasibility of a future  
10 randomised controlled trial of invasive urodynamic testing prior to surgery for stress  
11 urinary incontinence in women. *Health Technol Assess* 2015;19(15):1-274.
- 12 [28] Nager, CW, Brubaker, L, Litman, HJ, Zyczynski, HM, Varner, RE, Amundsen, C,  
13 et al. A randomized trial of urodynamic testing before stress- incontinence surgery. *N*  
14 *Engl J Med* 2012;366: 1987– 97.
- 15 [29] Romero, MJ, Ortiz, GMA, Gomez, PL. Does pressure flow study improve the outcome  
16 of surgery in women with SUI? *Eur Urol Suppl* 2010;9:228.
- 17 [30] Van Leijssen SAL, Kluivers, KB, Mol, BW, Broekhuis, SR, Milani, AL, Bongers, MY,  
18 et al. Can preoperative urodynamic investigation be omitted in women with stress urinary  
19 incontinence? A non- inferiority randomised controlled trial. *Neurourol Urodyn*  
20 2012;31:1118– 23.
- 21 [31] Agarwal A, Rathi S, Patnaik P, Shaw D, Jain M, Trivedi S et al., Does preoperative  
22 urodynamic testing improve surgical outcomes in patients undergoing the transobturator  
23 table procedure for stress urinary incontinence? A prospective randomised trial. *Korean J*  
24 *Urol* 2014; 55(12): 821-827.
- 25 [32] National Institute for Health and Care Excellence (2019) Urinary incontinence and  
26 pelvic organ prolapse in women: management (NICE Guideline 123). Available at:  
27 <https://www.nice.org.uk/guidance/ng123/chapter/Recommendations> [Accessed:  
28 05.06.19].
- 29 [33] van Leijssen SAL, Evert JSH Van, Mol BWJ, Vierhout ME, Milani AL, Heesakkers J, et  
30 al. The correlation between clinical and urodynamic diagnosis in classifying the type of  
31 urinary incontinence in women. A systematic review of the literature. *Neurourol Urodyn*  
32 2011;30(4):495–502.
- 33 [34] Paick JS, Ku JH, Shin JW, Son H, Oh SJ, Kim SW. Tension-free vaginal tape procedure  
34 for urinary incontinence with low Valsalva leak point pressure. *J Urol* 2004;172(4  
35 D):1370–3.
- 36 [35] O'Connor R, Nanigian D, Lyon M, Ellison L, Bales G, Stone A. Early outcomes of mid-  
37 urethral slings for female stress urinary incontinence stratified by valsalva leak point  
38 pressure. *Neurourol Urodyn* 2006;25(7):685-688.
- 39 [36] Houwert RM, Venema PL, Aquarius AE, Bruinse HW, Roovers JPWR, Vervest HAM.  
40 Risk factors for failure of retropubic and transobturator midurethral slings. *Obstet*  
41 *Gynecol Surv* 2009;64(12):795–6.
- 42 [37] van Leijssen SAL, Kluivers K, Mol B, Vierhout M, Heesakkers J. The value of  
43 preoperative urodynamics according to gynecologists and urologists with special interest  
44 in stress urinary incontinence. *Int Urogynecol J* 2011;23(4):423-428.
- 45 [38] Riad M, Familusi A, El Sayed M, Abdel-Fattah M. Current practice in the UK for the  
46 assessment and management of recurrent stress urinary incontinence in women. *Int*  
47 *Urogynecol J* 2011;22(Suppl 1):S1–195.
- 48 [39] Sirls LT, Richter HE, Litman HJ, Kenton K, Lemack GE, Lukacz ES, et al. The effect of  
49 urodynamic testing on clinical diagnosis, treatment plan and outcomes in women  
50 undergoing stress urinary incontinence surgery. *J Urol* 2013;189(1):204–9.
- 51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [40] Cho ST, Song HC, Song HJ, Lee YG, Kim KK. Predictors of postoperative voiding  
2 dysfunction following transobsturator sling procedures in patients with stress urinary  
3 incontinence. *Int Neurourol J* 2010;14(1):26–33.
- 4 [41] Mostafa A, Madhuvrata P, Abdel-Fattah M. Preoperative urodynamic predictors of  
5 short-term voiding dysfunction following a transobturator tension-free vaginal tape  
6 procedure. *Int J Gynecol Obstet* 2011;115(1):49–52.
- 7 [42] Homer T, Shen J, Vale L, McColl E, Tincello DG, Hilton P. Invasive urodynamic testing  
8 prior to surgical treatment for stress urinary incontinence in women: Cost-effectiveness  
9 and value of information analyses in the context of a mixed methods feasibility study.  
10 *Pilot Feasibility Stud* 2018;4(1):1–11.
- 11 [43] Norton P, Nager C, Brubaker L, Lemack G, Sirls L, Holley R et al. The cost of  
12 preoperative urodynamics: A secondary analysis of the ValUE trial. *Neurourol Urodyn*  
13 2014;35(1):81-84.
- 14 [44] Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: Do we  
15 need urodynamics? *Neurourol Urodyn* 2003;22(2):105–8.
- 16 [45] Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P.  
17 Urodynamic results and clinical outcomes with intradetrusor injections of  
18 onabotulinumtoxinA in a randomised, placebo-controlled dose-finding study in idiopathic  
19 overactive bladder. *Neurourol Urodyn* 2011;30(4):556-562.
- 20 [46] Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence  
21 and botulinum A injection. *J Urol* 2008;180:217-22.
- 22 [47] Groenendijk PM, Lycklama a Nyeholt AA, Heesakkers JP, et al. Urodynamic evaluation  
23 of sacral neuromodulation for urge urinary incontinence. *BJU Int* 2008;101:325-9.
- 24 [48] FUTURE [Internet]. W3.abdn.ac.uk. 2019 [cited 10 March 2019]. Available from:  
25 <https://w3.abdn.ac.uk/hsru/FUTURE/Public/Public/index>.
- 26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

**Table 1:** Included studies and their characteristics for the three systematic reviews.

Study reference	Design	Participant characteristics	Clinical evaluation and urodynamics (I)	Clinical evaluation only (C)	Follow-up (FU)	Patient-reported success	Objective success
<b>Non – surgical treatment (SUI and OAB)</b>							
Majumdar et al., 2010 [24]	Single-centre patient preference trial with embedded RCT, UK	<p><u>Inclusion criteria:</u> &gt;18 years old with UI and other LUTS</p> <p><u>Exclusion criteria:</u> Patients referred for POP surgery (<math>\geq</math>stage 2), previous consultation and referral for incontinence surgery, neurological disorders, previous incontinence treatment at tertiary level, recurrent dysuria or positive urine culture.</p> <p>Lost to FU: (I) 10 and (C) 14</p>	UDS  n=52	History, urine dipstick, 3-day bladder diary  n=47	5-6 months	N/A	Incontinence episode frequency based on 3-day bladder diary
Holtedahl et al., 2000 [25]	Multi-centre population-based RCT, Norway	<p><u>Inclusion criteria:</u> Women with <math>\geq 2</math> leakage episodes per month. Leakage was demonstrated either by a positive stress test, positive 48hr pad test or “wet” recording in a 48hr frequency/volume chart.</p> <p><u>Exclusion criteria:</u> Cardiac pacemaker, dementia and psychological or medical problems that might affect treatment.</p> <p>Lost to FU: (I) 2 and (C) 3</p>	PVR, UPP, stress test, pad weighing before and after split jumps, cystometry, cystoflowmetry, cystoscopy and gynaecological examination.  Women received treatment 6 months after initial consultation  n=46	Examination by general practitioner.  Women received treatment immediately after diagnosis  n=44	6, 12 months	Total number of women 'cured' (no reported leakage + 0 wet episodes) and 'improved' (improvement in at least 2/4 of: frequency, amount, impact, wet episodes consistent with pad test results and health workers feedback)	N/A
Ramsay et al., 1995 [22]	Single-centre RCT, UK	<p><u>Inclusion criteria:</u> Women with frequency, urgency, nocturia, UII and SUI.</p> <p><u>Exclusion criteria:</u></p>	UDS  n=27	Clinical evaluation  n=33	3 months	Cure/ improvement rate based on the questions: “Are you cured?” or “Are you improved to the extent that you do	Dry on pad test


		Previous incontinence treatment, haematuria, recurrent dysuria/voiding difficulty and positive urine culture.  Lost to FU: (I) 7 and (C) 5				not require any further treatment?"	
Khullar et al., 2000 [23]	Single-centre RCT, UK	<u>Inclusion criteria:</u> Women with urinary symptoms without a UDS diagnosis. Total number of patients randomised: 105  Total lost to FU: n=41	4-hour ambulatory UDS	Clinical evaluation	3 years	Urinary symptoms using questionnaire	N/A
<b>Surgical treatment – SUI</b>							
Choe, 2001[26]	RCT, USA (conference abstract)	<u>Inclusion criteria:</u> Women with type II/III SUI  Lost to FU: 0	Multichannel UDS  n=40	Urethroscopy, Q-tip test and supine cough stress test n=40	36 months (mean)	N/A	No urine loss with physical activity
Hilton et al., 2015 [27]	Multi-centre pilot RCT, UK [INVESTIGATE – I]	<u>Inclusion criteria:</u> SUI or stress predominant MUI, family complete and had previous conservative treatment (single PFMT ± other) with inadequate symptom resolution.  <u>Exclusion criteria:</u> Symptomatic uterovaginal prolapse requiring treatment, previous surgery for UI/POP, UDS ≤ 3 year ago and neurological cause of UI.  Lost to FU: (I) 75 and (C) 55	Dual-channel subtracted cystometry with simultaneous PFS, VUDS and ambulatory urodynamics at clinician's discretion  n=112	Clinical assessment and non-invasive tests at clinician's discretion (i.e. frequency/volume charts or bladder diary, MSSU, urine flow rate, PVR)  n=110	6 months	Number without any incontinence within the first year	N/A
Nager et al., 2012 [28]	Multi-centre, noninferiority RCT, USA [VALUE]	<u>Inclusion criteria:</u> Uncomplicated, stress predominant UI >21 years old, duration ≥3 months, MESA questionnaire: SUI score > UI score, PVR <150ml, negative urinalysis/urine culture, assessment of urethral mobility, positive	Non-instrumented uroflowmetry, filling cystometry with VLPP & PFS and optional UPP & VUDS	SUI symptoms, stress test, PVR, urine dipstick, standing and straining	After discharge, 3 and 12 months	Reduction in UDI score by ≥ 70% at 12 months and a PGI-I response of "very much better" or "much better"	Negative stress test on examination



		<p>stress test</p> <p><u>Exclusion criteria:</u> Previous UI surgery, pelvic surgery ≤3 months, pelvic irradiation, anterior/apical prolapse ≥1cm distal to the hymen</p> <p>Lost to FU: (I) 43 and (C) 49</p>	n = 315	<p>prolapse exam, assessment of urethral mobility (Q-Tip test, visual inspection, palpation, point Aa on POP-Q exam or lateral cystogram)</p> <p>n = 315</p>			
Romero et al., 2010 [29]	RCT, Spain (conference abstract)	<p><u>Inclusion criteria:</u> Women with SUI/MUI</p> <p><u>Exclusion criteria:</u> &lt;18 years, previous radiotherapy or UI procedure</p> <p>Lost to FU: 0</p>	<p>Measurements of MCC, voiding pressure, Qmax, VLPP and DOA</p> <p>n=42</p>	<p>History, physical evaluation with full bladder, flowmetry, and PVR</p> <p>n=44</p>	(I) 46 months (C) 49 months	ICIQ-SF: "How often do you leak urine?" (either never, once/week, 2-3 times/week or once/day)	Dry on cough test
van Leijssen et al., 2012 [30]	Multicentre noninferiority RCT, Netherlands [VUSIS]	<p><u>Inclusion criteria:</u> SUI or stress predominant MUI demonstrated on physical examination and/or micturition diary, failed conservative therapy</p> <p><u>Exclusion criteria:</u> Previous UI surgery, ≥POP-Q stage 3 and/or PVR &gt;150ml on US or catheterisation</p> <p>Lost to FU: 0</p>	<p>Free flow and PVR measurement, filling cystometry with ALPP and PFS ± UPP</p> <p>n=31</p>	<p>History and physical examination, 48hr bladder diary, 48hr pad test, urinalysis and PVR</p> <p>n=28</p>	6 weeks 6, 12 and 24 months	UDI-6: "urine leakage related to physical activity, coughing or sneezing" (negative answer)	Negative stress test
Agarwal et al. 2014 [31]	RCT, India	<p><u>Inclusion criteria:</u> Uncomplicated SUI (≥ 3 months), failed non-surgical treatment, PVR &lt;150ml, negative urine culture, assessment of urethral mobility, positive stress test</p> <p><u>Exclusion criteria:</u></p>	<p>Non-invasive uroflowmetry, filling cystometry with VLPP &amp; PFS, stress test and UPP</p>	<p>History, PVR measurement, urine culture, stress test, urethral mobility</p>	6, 12 months	Reduction in UDI-6 score by ≥ 70%	Negative stress test


		Previous UI surgery, pelvic surgery $\leq 3$ months, pelvic irradiation, anterior/apical prolapse $\geq 1$ cm distal to the hymen		assessment			
<b>Invasive treatment – OAB</b>							
No studies found							

Abbreviations: SUI (stress urinary incontinence), OAB (overactive bladder), UI (urinary incontinence), LUTS (lower urinary tract symptoms), POP (pelvic organ prolapse), UDS (urodynamics), PVR (post void residual), UPP (urethra pressure profile), UUI (urgency urinary incontinence), MUI (mixed urinary incontinence), PFMT (pelvic floor muscle training), PFS (pressure flow studies), VUDS (video-urodynamics), MSSU (mid-stream specimen urine), MESA (Medical, Epidemiological and Social Aspects of Ageing Questionnaire), UDI (Urogenital Distress Inventory), PGI-I (patient global impression of improvement), MCC (maximum cystometric capacity), Qmax (maximum flow rate), VLPP (Valsalva leak-point pressure), (DOA (detrusor overactivity), ICIQ - SF (International Consultation on Incontinence Questionnaire - short form), US (ultrasound scan), ALPP (abdominal leak-point pressure)




**Figure 1.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) chart showing the literature search results and the selection process for the review of urodynamic versus clinical evaluation only prior to non-surgical management of women with urinary incontinence (stress urinary incontinence and overactive bladder).

(a)




(b)



**Figure 2.** Success after non-surgical management: (a) patient-reported success; (b) objective success


(a)



(b)


	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Holtedahl et al. 2000	+	+	?	+	+
Khullar et al. 2000	?	?	?	-	-
Majumdar et al. 2010	+	+	+	-	-
Ramsay et al. 1995	+	?	+	+	+

**Figure 3.** Risk of bias (a) graph (b) summary for non-surgical management of urinary incontinence




**Figure 4.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) chart showing the literature search results and the selection process for the review of urodynamic versus clinical evaluation only prior to surgical management of women with stress urinary incontinence.


(a)



(b)




**Figure 5.** Success after surgical management of stress urinary incontinence: (a) patient-reported success; (b) objective success



**Figure 6.** Adverse events after surgical management of stress urinary incontinence

(a)




(b)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Agarwal et al. 2014	?	?	?	-	-
Choe 2001	?	?	?	+	-
Hilton et al. 2015	+	+	-	-	+
Khullar et al. 2000	?	?	?	-	-
Nager et al. 2012	+	-	+	-	+
Romero et al. 2010	?	?	?	+	+
Van Leijssen et al. 2012	+	+	-	+	+

**Figure 7** Risk of bias (a) graph (b) summary for surgical management of stress urinary incontinence





**Figure 8.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) chart showing the literature search results and the selection process for the review of urodynamic versus clinical evaluation only prior to invasive management of women with overactive bladder/urgency urinary incontinence.

### Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

M.A.F is the chief investigator and A.M. is a co-investigator on the ongoing National Institute for Health Research (NIHR)-funded FUTURE Study evaluating the clinical and cost effectiveness of urodynamics in women with refractory overactive bladder symptoms (<https://w3.abdn.ac.uk/hsru/FUTURE/Public/Public/index>). They are also part of the team applying for further relevant NIHR funding. Professor Abdel-Fattah and Dr. Mostafa have no potential conflicts of interest for this study. For the full declaration by Professor Abdel-Fattah please see this weblink <https://www.abdn.ac.uk/iahs/research/obsgynae/profiles/m.abdelfattah>. K.Y.L and M.S. report no conflict of interest.

**\*Manuscript (including track changes)**  
[Click here to view linked References](#)

Hi there

Here is the dummy versions of the files.

BW

Alyaa